Roles of CREB-binding protein (CBP)/p300 in respiratory epithelium tumorigenesis

Cell Research

Volumn 17, Issue 4, 2007, Pages 324-332

  Karamouzis, Michalis V ^a   Konstantinopoulos, Panagiotis A ^a,b   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Acetylation; CBP; Lung cancer; p300; Transcription factor

Indexed keywords

HISTONE ACETYLTRANSFERASE PCAF; TRANSCRIPTION FACTOR;

ACETYLATION; ANIMAL; CELL TRANSFORMATION; DNA REPAIR; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; RESPIRATORY TRACT MUCOSA; REVIEW; TRANSACTIVATION;

ACETYLATION; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DNA REPAIR; HUMANS; LUNG NEOPLASMS; MUTATION; P300-CBP TRANSCRIPTION FACTORS; RESPIRATORY MUCOSA; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS;

EID: 34247343188     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2007.10     Document Type: Review

References (78)

1. Chrivia JC, Kwok RP, Lamb N, Hagiwara M, Montminy MR, Goodman RH. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 1993; 365:855-859.
2. 2 Eckner R, Ewen ME, Newsome D, et al. Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev 1994; 8:869-884.
3. Janknecht R. The versatile functions of the transcriptional coactivators p300 and CBP and their roles in disease. Histol Histopathol 2002; 17:657-668.
4. Goodman RH, Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev 2000; 14:1553-1577.
5. Chan HM, La Thangue NB. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 2001; 114:2363-2373.
6. Yao TP, Oh SP, Fuchs M, et al. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 1998; 93:361-372.
7. Oike Y, Hata A, Mamiya T, et al. Truncated CBP protein leads to classical Rubinstein-Taybi syndrome phenotypes in mice: implications for a dominant-negative mechanism. Hum Mol Genet 1999; 8:387-396.
8. Johannessen M, Delghandi MP, Moens U. What turns CREB on? Cell Signal 2004; 16:1211-1227.
9. Petrij F, Giles RH, Dauwerse HG, et al. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 1995; 376:348-351.
10. Petrij F, Dorsman JC, Dauwerse HG, et al. Rubinstein-Taybi syndrome caused by a de novo reciprocal translocation t(2;16)(q36.3; p13.3). Am J Med Genet 2000; 92:47-52.
11. Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene 2004; 23:4225-4231.
12. Ionov Y, Nowak N, Perucho M, Markowitz S, Cowell JK. Manipulation of nonsense mediated decay identifies gene mutations in colon cancer cells with microsatellite instability. Oncogene 2004; 23:639-645.
13. Shigeno K, Yoshida H, Pan L, et al. Disease-related potential of mutations in transcriptional cofactors CREB-binding protein and p300 in leukemias. Cancer Lett 2004; 213:11-20.
14. Merika M, Williams AJ, Chen G, Collins T, Thanos D. Recruitment of CBP/p300 by the IFN beta enhanceosome is required for synergistic activation of transcription. Mol Cell 1998; 1:277-287.
15. Konstantinopoulos PA, Papavassiliou AG. Chromatin-modulating agents as epigenetic anticancer drugs - 'the die is cast'. Drug Discov Today 2006; 11:91-93.
16. Allard S, Masson JY, Cote J. Chromatin remodeling and the maintenance of genome integrity. Biochim Biophys Acta 2004; 1677:158-164.
17. Manning ET, Ikehara T, Ito T, Kadonaga JT, Kraus WL. p300 forms a stable, template-committed complex with chromatin: role for the bromodomain. Mol Cell Biol 2001; 21:3876-3887.
18. Shikama N, Chan HM, Krstic-Demonacos M, et al. Functional interaction between nucleosome assembly proteins and p300/CREB-binding protein family coactivators. Mol Cell Biol 2000; 20:8933-8943.
19. Kalkhoven E. CBP and p300: HATs for different occasions. Biochem Pharmacol 2004; 68:1145-1155.
20. Fu M, Wang C, Zhang X, Pestell RG. Acetylation of nuclear receptors in cellular growth and apoptosis. Biochem Pharmacol 2004; 68:1199-1208.
21. Nadiminty N, Lou W, Lee SO, Lin X, Trump DL, Gao AC. Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation. Proc Natl Acad Sci USA 2006; 103:7264-7269.
22. Ryan CM, Harries JC, Kindle KB, Collins HM, Heery DM. Functional interaction of CREB binding protein (CBP) with nuclear transport proteins and modulation by HDAC inhibitors. Cell Cycle 2006; 5:2146-2152.
23. Debes JD, Sebo TJ, Heemers HV, et al. p300 modulates nuclear morphology in prostate cancer. Cancer Res 2005; 65:708-712.
24. Muth V, Nadaud S, Grummt I, Voit R. Acetylation of TAF(I)68, a subunit of TIF-IB/SL1, activates RNA polymerase I transcription. EMBO J 2001; 20:1353-1362.
25. Ogryzko VV, Kotani T, Zhang X, et al. Histone-like TAFs within the PCAF histone acetylase complex. Cell 1998; 94:35-44.
26. Vandel L, Trouche D. Physical association between the histone acetyl transferase CBP and a histone methyl transferase. EMBO Rep 2001; 2:21-26.
27. Kamei Y, Xu L, Heinzel T, et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996; 85:403-414.
28. Karamouzis MV, Papadas T, Varakis I, Sotiropoulou-Bonikou G, Papavassiliou AG. Induction of the CBP transcriptional coactivator early during laryngeal carcinogenesis. J Cancer Res Clin Oncol 2002; 128:135-140.
29. Arany Z, Newsome D, Oldread E, Livingston DM, Eckner R. A family of transcriptional adaptor proteins targeted by the E1A oncoprotein. Nature 1995; 374:81-84.
30. Patel D, Huang SM, Baglia LA, McCance DJ. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J 1999; 18:5061-5072.
31. Ait-Si-Ali S, Carlisi D, Ramirez S, et al. Phosphorylation by p44 MAP kinase/ERK1 stimulates CBP histone acetyl transferase activity in vitro. Biochem Biophys Res Commun 1999; 262:157-162.
32. Huang WC, Chen CC. Akt phosphorylation of p300 at Ser-1834 is essential for its histone acetyltransferase and transcriptional activity. Mol Cell Biol 2005; 25:6592-6602.
33. Chevillard-Briet M, Trouche D, Vandel L. Control of CBP co-activating activity by arginine methylation. EMBO J 2002; 21:5457-5466.
34. Girdwood D, Bumpass D, Vaughan OA, et al. P300 transcriptional repression is mediated by SUMO modification. Mol Cell 2003; 11:1043-1054.
35. Thompson PR, Wang D, Wang L, et al. Regulation of the p300 HAT domain via a novel activation loop. Nat Struct Mol Biol 2004; 11:308-315.
36. Qiu Y, Zhao Y, Becker M, et al. HDAC1 acetylation is linked to progressive modulation of steroid receptor-induced gene transcription. Mol Cell 2006; 22:669-679.
37. Thomas MC, Chiang CM. E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol Cell 2005; 17:251-264.
38. Black JC, Choi JE, Lombardo SR, Carey M. A mechanism for coordinating chromatin modification and preinitiation complex assembly. Mol Cell 2006; 23:809-818.
39. Guermah M, Palhan VB, Tackett AJ, Chait BT, Roeder RG. Synergistic functions of SII and p300 in productive activator-dependent transcription of chromatin templates. Cell 2006; 125:275-286.
40. Ozdag H, Batley SJ, Forsti A, et al. Mutation analysis of CBP and PCAF reveals rare inactivating mutations in cancer cell lines but not in primary tumours. Br J Cancer 2002; 87:1162-1165.
41. Panani AD, Roussos C. Cytogenetic and molecular aspects of lung cancer. Cancer Lett 2006; 239:1-9.
42. Kishimoto M, Kohno T, Okudela K, et al. Mutations and deletions of the CBP gene in human lung cancer. Clin Cancer Res 2005; 11:512-519.
43. Gayther SA, Batley SJ, Linger L, et al. Mutations truncating the EP300 acetylase in human cancers. Nat Genet 2000; 24:300-303.
44. Suganuma T, Kawabata M, Ohshima T, Ikeda MA. Growth suppression of human carcinoma cells by reintroduction of the p300 coactivator. Proc Natl Acad Sci USA 2002; 99:13073-13078.
45. Turnell AS, Stewart GS, Grand RJ, et al. The APC/C and CBP/p300 cooperate to regulate transcription and cell-cycle progression. Nature 2005; 438:690-695.
46. Turnell AS, Mymryk JS. Roles for the coactivators CBP and p300 and the APC/C E3 ubiquitin ligase in E1A-dependent cell transformation. Br J Cancer 2006; 95:555-560.
47. Coutts AS, La Thangue NB. The p53 response: emerging levels of co-factor complexity. Biochem Biophys Res Commun 2005; 331:778-785.
48. Sun Y. p53 and its downstream proteins as molecular targets of cancer. Mol Carcinog 2006; 45:409-415.
49. Livengood JA, Scoggin KE, Van Orden K, et al. p53 transcriptional activity is mediated through the SRC1-interacting domain of CBP/p300. J Biol Chem 2002; 277:9054-9061.
50. Demarest SJ, Martinez-Yamout M, Chung J, et al. Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators. Nature 2002; 415:549-553.
51. Ito A, Lai CH, Zhao X, et al. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 2001; 20:1331-1340.
52. Grossman SR, Perez M, Kung AL, et al. p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell 1998; 2:405-415.
53. Grossman SR, Deato ME, Brignone C, et al. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 2003; 300:342-344.
54. Tsantoulis PK, Gorgoulis VG. Involvement of E2F transcription factor family in cancer. Eur J Cancer 2005; 41:2403-2414.
55. Gorgoulis VG, Zacharatos P, Mariatos G, et al. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol 2002; 198:142-156.
56. Major ML, Lepe R, Costa RH. Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylation-dependent recruitment of p300/CBP coactivators. Mol Cell Biol 2004; 24:2649-2661.
57. Ianari A, Gallo R, Palma M, Alesse E, Gulino A. Specific role for p300/CREB-binding protein-associated factor activity in E2F1 stabilization in response to DNA damage. J Biol Chem 2004; 279:30830-30835.
58. Karamouzis MV, Papavassiliou AG. Retinoid receptor cross-talk in respiratory epithelium cancer chemoprevention. Trends Mol Med 2005; 11:10-16.
59. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview. Cyclin D1: normal and abnormal functions. Endocrinology 2004; 145:5439-5447.
60. Fu M, Wang C, Rao M, et al. Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanism. J Biol Chem 2005; 280:29728-29742.
61. Chen LC, Chen BK, Chang JM, Chang WC. Essential role of c-Jun induction and coactivator p300 in epidermal growth factor-induced gene expression of cyclooxygenase-2 in human epidermoid carcinoma A431 cells. Biochim Biophys Acta 2004; 1683:38-48.
62. Karamouzis MV, Papavassiliou AG. COX-2 inhibition in cancer therapeutics: a field of controversy or a magic bullet? Expert Opin Invest Drugs 2004; 13:359-372.
63. Karamouzis MV, Sotiropoulou-Bonikou G, Vandoros G, Varakis I, Papavassiliou AG. Retinoid-X-receptor alpha (RXRalpha) expression during laryngeal carcinogenesis: detrimental or beneficial event? Cancer Lett 2003; 199:175-183.
64. Wacheck V, Zangemeister-Wittke U. Antisense molecules for targeted cancer therapy. Crit Rev Oncol Hematol 2006; 59:65-73.
65. Schlee M, Hornung V, Hartmann G. siRNA and isRNA: two edges of one sword. Mol Ther 2006; 14:463-470.
66. Gonzalez-Ruiz D, Gohlke H. Targeting protein-protein interactions with small molecules: challenges and perspectives for computational binding epitope detection and ligand finding. Curr Med Chem 2006; 13:2607-2625.
67. Leong PL, Andrews GA, Johnson DE, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 2003; 100:4138-4143.
68. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5:769-784.
69. Cullis PM, Wolfenden R, Cousens LS, Alberts BM. Inhibition of histone acetylation by N-[2-(S-coenzyme A)acetyl] spermidine amide, a multisubstrate analog. J Biol Chem 1982; 257:12165-12169.
70. Lau OD, Kundu TK, Soccio RE, et al. HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol Cell 2000; 5:589-595.
71. Cebrat M, Kim CM, Thompson PR, Daugherty M, Cole PA. Synthesis and analysis of potential prodrugs of coenzyme A analogues for the inhibition of the histone acetyltransferase p300. Bioorg Med Chem 2003; 11:3307-3313.
72. Sagar V, Zheng W, Thompson PR, Cole PA. Bisubstrate analogue structure-activity relationships for p300 histone acetyltransferase inhibitors. Bioorg Med Chem 2004; 12:3383-3390.
73. Balasubramanyam K, Swaminathan V, Ranganathan A, Kundu TK. Small molecule modulators of histone acetyltransferase p300. J Biol Chem 2003; 278:19134-19140.
74. Sun Y, Jiang X, Chen S, Price BD. Inhibition of histone acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiation. FEBS Lett 2006; 580:4353-4356.
75. Varier RA, Swaminathan V, Balasubramanyam K, Kundu TK. Implications of small molecule activators and inhibitors of histone acetyltransferases in chromatin therapy. Biochem Pharmacol 2004; 68:1215-1220.
76. Balasubramanyam K, Varier RA, Altaf M, et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/non-histone proteins and histone acetyltransferase- dependent chromatin transcription. J Biol Chem 2004; 279:51163-51171.
77. Balasubramanyam K, Altaf M, Varier RA, et al. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J Biol Chem 2004; 279:33716-33726.
78. Stimson L, Rowlands MG, Newbatt YM, et al. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol Cancer Ther 2005; 4:1521-1532.